211 related articles for article (PubMed ID: 16283155)
1. [Consequences of the 12th AMG amendment on the conduct of non-commercial clinical trials].
Rossion I
Urologe A; 2005 Dec; 44(12):1444-8. PubMed ID: 16283155
[TBL] [Abstract][Full Text] [Related]
2. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
Schwarz S; Frölich L; Striebel JP; Hennerici MG
Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346
[No Abstract] [Full Text] [Related]
3. [The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials].
Dreier G; Marx C; Schmoor C; Maier-Lenz H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):445-52. PubMed ID: 15830256
[TBL] [Abstract][Full Text] [Related]
4. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
[TBL] [Abstract][Full Text] [Related]
5. [Reorganization of the procedures and the tasks of the responsible ethics committees after the 12th AMG amendment. Concepts of the permanent working group of the medical ethics committees in Germany].
Wessler I; Burger R; Doppelfeld E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):155-67. PubMed ID: 15726456
[TBL] [Abstract][Full Text] [Related]
6. [Clinical research with pharmaceutical agents in Germany: effects of the 12th amendment to the German Drug Law].
Götte D; Weihrauch TR
Internist (Berl); 2004 Jun; 45 Suppl 1():S48-54. PubMed ID: 15138642
[TBL] [Abstract][Full Text] [Related]
7. [The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations].
Kölch M; Lippert HD; Fegert JM
Z Kinder Jugendpsychiatr Psychother; 2006 Mar; 34(2):117-26. PubMed ID: 16610597
[TBL] [Abstract][Full Text] [Related]
8. [Non-commercial clinical trials--who will be the legal sponsor? Sponsorship of investigator-initiated clinical trials according to the German Drug Law].
Benninger-Döring G; Boos J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jul; 49(7):675-80. PubMed ID: 16763801
[TBL] [Abstract][Full Text] [Related]
9. [Effects of the 12th amendment to the German drug code on investigator-initiated clinical trials].
Kehrel U
Gesundheitswesen; 2011 Oct; 73(10):696-701. PubMed ID: 20859850
[TBL] [Abstract][Full Text] [Related]
10. [Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th Law Amending the German Drug Law].
Geisler I; Hofmann HP; Nickel L
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):141-6. PubMed ID: 15726454
[TBL] [Abstract][Full Text] [Related]
11. [The GCP directive--consequences for clinical drug research].
Gluud CN
Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
[TBL] [Abstract][Full Text] [Related]
12. [The community clinical trial system EudraCT at the EMEA for the monitoring of clinical trials in Europe].
Krafft H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):453-8. PubMed ID: 15830257
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of SUSARs. Clinical evaluation of single cases in terms of regulatory requirements].
Wroblewski H; Schmickler M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):459-63. PubMed ID: 15830258
[TBL] [Abstract][Full Text] [Related]
14. [GCP inspections of clinical trials].
Schwarz G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):181-8. PubMed ID: 15726459
[TBL] [Abstract][Full Text] [Related]
15. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
Georgias C; Grunow A; Olderog M; May A; Paulus U
Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
[TBL] [Abstract][Full Text] [Related]
16. [Clinical trials with minors in Germany--effects of the 12th amendment to the German Drug Code on the numbers of applications to Institutional Review Boards (IRB)].
Kölch M; Märsch C; Fegert JM; Lippert HD
Gesundheitswesen; 2009 Mar; 71(3):127-33. PubMed ID: 19221985
[TBL] [Abstract][Full Text] [Related]
17. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
Englev E; Petersen KP
Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
[TBL] [Abstract][Full Text] [Related]
18. [Development of an anticancer drug in Japan based on a new clinical trial system].
Nakashima H; Nakano S
Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
[TBL] [Abstract][Full Text] [Related]
19. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
Grienenberger A
J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
